The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Menlo Therapeutics Inc. Securities Settlement: SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF...
REDWOOD CITY, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the...
REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced results from its Phase 2 clinical trial...
REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast...
REDWOOD CITY, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment...
REDWOOD CITY, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd. PR Newswire NEW YORK, Nov. 12, 2019 NEW YORK, Nov. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible...
REDWOOD CITY, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment...
- Pivotal results expected in March/April 2020 - - Details of the program to be reviewed at company’s Investor Day today in NY - REDWOOD CITY, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Menlo...
-Management to Review Late Stage Development, NDA-readiness and Commercial Opportunity of Serlopitant- -Discussion to Feature two Prominent Key Opinion Leaders Well Versed in the Unmet Needs of...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約